Assembly Biosciences
NASDAQ:ASMBAssembly Biosciences, Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for the treatment of hepatitis B virus (HBV) infection in the United States. The company's next-generation HBV core inhibitors include ABI-4334, which is in Phase 1a studies for the treatment of HBV; and ABI-H3733, which is in Phase 1b clinical study. It is also involved in novel small molecule approaches for HBV and hepatitis delta virus (HDV) comprising an orally bioavailable HBV/HDV entry inhibitor and liver-focused interferon-a receptor agonist. In addition, the company develops Herpesvirus programs, such as ABI-5366 HSV-2, a long-acting helicase inhibitor; and pan-herpes non-nucleoside polymerase inhibitors for transplant-associated infections. Further, Assembly Biosciences, Inc. has collaboration agreement with BeiGene, Ltd. to develop and commercialize the novel core inhibitor product candidates for chronic HBV infection in the People's Republic of China, Hong Kong, Taiwan, and Macau; and clinical trial collaboration agreement with Arbutus Biopharma Corporation to conduct a randomized, multi-center, and open-label clinical trials, as well as agreement with Antios Therapeutics, Inc. for triple combination therapy. The company also has license agreement with Indiana University Research and Technology Corporation for HBV research, as well as a partnership with Gilead Sciences, Inc. to develop next-generation therapeutics for serious viral diseases. The company was formerly known as Ventrus Biosciences, Inc. and changed its name to Assembly Biosciences, Inc. in June 2014. Assembly Biosciences, Inc. was incorporated in 2005 and is headquartered in South San Francisco, California.
Magenta Therapeutics
NASDAQ:MGTAMagenta Therapeutics, Inc., a biotechnology company focus on improving stem cell transplantation. Its product candidates are designed to bring the curative power of stem cell transplant to patients with blood cancers, genetic diseases, and autoimmune diseases. The company's product portfolio includes MGTA-117, an anti-CD117 antibody conjugated to an amanitin payload that targets hematopoietic stem cells (HSCs) and leukemia cells; and MGTA-45, an anti-human CD45 antibody conjugated to a DNA-interacting payload for HSCs, leukemia cells, and immune cells. In addition, it focus on development of ADC-based conditioning program that targets a receptor of T cells; and novel conditioning and translation stem cell sciences, as well as develops cell therapy program, E478, which is a small molecule aryl hydrocarbon receptor antagonist for stem cell-based gene therapy and genome editing. In addition, the company has a research and clinical collaboration agreement with AVROBIO, Inc. for the treatment of lysosomal storage disorders; and Beam Therapeutics, Inc. to evaluate the potential utility of MGTA-117 for conditioning of patients with sickle cell disease and beta-thalassemia. Magenta Therapeutics, Inc. was formerly known as HSCTCo Therapeutics, Inc. and changed its name to Magenta Therapeutics, Inc. in February 2016. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Satsuma Pharmaceuticals
NASDAQ:STSASatsuma Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, developing novel therapeutic products for the acute treatment of migraines. The company's lead product candidate is STS101, a drug-device combination of a proprietary dry-powder formulation of dihydroergotamine mesylate, which is in SUMMIT Phase 3 efficacy trials and can be self-administered with proprietary pre-filled, single-use, and nasal delivery device. Satsuma Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.
Sinovac Biotech
NASDAQ:SVASinovac Biotech Ltd., a biopharmaceutical company, focuses in the research, development, manufacture, and commercialization of vaccines against human infectious diseases in the People's Republic of China. The company's product portfolio includes vaccines against hepatitis A and B; hand, foot, and mouth diseases caused by enterovirus 71 (EV71); seasonal influenza; H5N1 and H1N1 pandemic influenza; coronavirus; varicella; and mumps. Its marketed products include Healive, an inactivated hepatitis A vaccine; Bilive, a combined inactivated hepatitis A and B vaccine; Anflu, a split viron influenza vaccine; Panflu, a vaccine against the H5N1 influenza virus; Panflu.1, a vaccine against the influenza A H1N1 virus; mumps vaccine to treat viral disease in human species; split viron pandemic influenza vaccine; and Inlive, an EV71 vaccine. The company also offers varicella, a vaccine to treat contagious infectious disease; pneumococcal polysaccharide vaccine, a vaccine to prevent streptococcus pneumoniae infections, such as pneumonia and septicemia; quadrivalent influenza vaccine, a vaccine to protect against two influenza A viruses and two influenza B viruses; and CoronaVac, a vaccine against COVID-19. In addition, its pipeline products include sabin inactivated polio vaccine, a vaccine to treat Poliomyelitis that has completed phase III clinical trial; and rubella vaccine. The company has collaboration agreements with GlaxoSmithKline Biologicals SA to develop combination vaccines containing measles for the China market; Tianjin CanSino Biotechnology Inc. to develop a pneumococcal vaccine; and Instituto Butantan to advance the clinical trials of CoronaVac, an inactivated vaccine candidate against COVID-19 to Phase III. Sinovac Biotech Ltd. was founded in 1993 and is headquartered in Beijing, the People's Republic of China.
TherapeuticsMD
NASDAQ:TXMDTherapeuticsMD, Inc. operates as a pharmaceutical royalty company in the United States. It has a license agreement with Mayne Pharma to commercialize the IMVEXXY, BIJUVA, and ANNOVERA prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brand names. The company sells its prescription pharmaceutical products and prenatal vitamin products through wholesale distributors and retail pharmacy distributors. TherapeuticsMD, Inc. was founded in 2008 and is headquartered in Boca Raton, Florida.